Medtronic PLC $MDT Shares Sold by Triglav Investments D.O.O.

Triglav Investments D.O.O. reduced its holdings in Medtronic PLC (NYSE:MDT) by 16.7% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 49,999 shares of the medical technology company’s stock after selling 10,000 shares during the quarter. Triglav Investments D.O.O.’s holdings in Medtronic were worth $4,359,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. 1248 Management LLC bought a new position in Medtronic in the first quarter worth about $26,000. Columbia River Financial Group LLC acquired a new stake in shares of Medtronic during the 1st quarter worth approximately $28,000. Twin Tree Management LP bought a new stake in shares of Medtronic in the 1st quarter worth approximately $29,000. Activest Wealth Management boosted its position in Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after purchasing an additional 322 shares during the period. Finally, Hughes Financial Services LLC bought a new position in Medtronic during the 1st quarter worth $32,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Trading Down 0.2%

Medtronic stock opened at $90.82 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. The firm has a market cap of $116.49 billion, a price-to-earnings ratio of 25.02, a price-to-earnings-growth ratio of 2.42 and a beta of 0.78. The firm’s 50 day moving average price is $94.35 and its two-hundred day moving average price is $89.72. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $99.37.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.23 by $0.03. The business had revenue of $8.58 billion during the quarter, compared to the consensus estimate of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.Medtronic’s revenue was up 7.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, research analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 17th. Stockholders of record on Friday, September 26th were issued a $0.71 dividend. The ex-dividend date was Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.1%. Medtronic’s dividend payout ratio is presently 78.24%.

Wall Street Analyst Weigh In

MDT has been the topic of a number of recent research reports. Robert W. Baird raised their target price on Medtronic from $94.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, August 20th. BTIG Research reaffirmed a “neutral” rating on shares of Medtronic in a report on Friday, July 11th. Citigroup boosted their target price on shares of Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Sanford C. Bernstein restated an “outperform” rating and issued a $98.00 target price on shares of Medtronic in a research report on Friday. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $107.00 price target (up previously from $98.00) on shares of Medtronic in a report on Tuesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $102.82.

Insider Buying and Selling at Medtronic

In other Medtronic news, Director William R. Jellison purchased 2,500 shares of the stock in a transaction dated Monday, August 25th. The shares were acquired at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the acquisition, the director owned 5,000 shares of the company’s stock, valued at $461,850. This represents a 100.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the sale, the executive vice president directly owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.26% of the company’s stock.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.